Aditi Kumar, MD, endocrinology fellow at the University of Mississippi, discusses aggressive multimodal therapy in anaplastic thyroid cancer. A study conducted at the Mayo Clinic, where Kumar was previously a fellow, looked at 29 patients with stage IV, A, B and C anaplastic thyroid cancer, a rare form of thyroid cancer with poor outcomes. Often, patients are not treated at this stage, as options are limited and toxicities from treatments can be high, says Kumar.
